Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sunitinib Malate

FDA-approved product (capsule, oral), marketed as Sunitinib Malate, Sutent.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sunitinib Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Gastrointestinal stromal tumor
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic neuroendocrine tumor
  • Papillary renal cell carcinoma
  • Renal cell adenocarcinoma
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sunitinib Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sunitinib Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

    NCT01664182 · start 2012-08-01

    Registered record
    Registry ID
    NCT01664182
    Conditions
    Advanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    Interventions
    Bevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate; Trebananib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2020-12-07
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Renal Cell Carcinoma; Advanced Sarcomatoid Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v7; Stage IV Renal Cell Cancer AJCC v7
    InterventionBevacizumab; Pazopanib Hydrochloride; Sorafenib Tosylate; Sunitinib Malate +1 more
    PhasePhase 2
    Registry statusCompleted

  • A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

    NCT01396148 · start 2012-06

    Registered record
    Registry ID
    NCT01396148
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    sunitinib malate dose escalation; sunitinib malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2017-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    Interventionsunitinib malate dose escalation; sunitinib malate
    PhasePhase 2
    Registry statusCompleted

  • Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule

    NCT01499121 · start 2012-05

    Registered record
    Registry ID
    NCT01499121
    Conditions
    Clear Cell, Metastatic Renal Cell Carcinoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-05
    Completion
    2017-09-30
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell, Metastatic Renal Cell Carcinoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusCompleted

  • First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

    NCT01371201 · start 2011-12-22

    Registered record
    Registry ID
    NCT01371201
    Conditions
    Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
    Interventions
    Sunitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-12-22
    Completion
    2021-04-20
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
    InterventionSunitinib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

    NCT01718327 · start 2011-09-01

    Registered record
    Registry ID
    NCT01718327
    Conditions
    Unresectable and Advanced Cholangiocarcinoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09-01
    Completion
    2016-11-17
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnresectable and Advanced Cholangiocarcinoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusCompleted

  • Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma

    NCT01070186 · start 2010-10

    Registered record
    Registry ID
    NCT01070186
    Conditions
    Renal Cell Carcinoma
    Interventions
    Sunitinib; Tumor biopsy; Nephrectomy; Biomarkers
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionSunitinib; Tumor biopsy; Nephrectomy; Biomarkers
    PhasePhase 2
    Registry statusWithdrawn

  • Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

    NCT01243359 · start 2010-10

    Registered record
    Registry ID
    NCT01243359
    Conditions
    Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sunitinib malate; bevacizumab; pharmacological study; laboratory biomarker analysis; fluorine F 18 fluorothymidine; positron emission tomography; computed tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10
    Completion
    Not recorded
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage I Renal Cell Cancer; Stage II Renal Cell Cancer +3 more
    Interventionsunitinib malate; bevacizumab; pharmacological study; laboratory biomarker analysis +3 more
    PhasePhase 1
    Registry statusCompleted

  • Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

    NCT00905021 · start 2010-03

    Registered record
    Registry ID
    NCT00905021
    Conditions
    Metastatic Breast Cancer
    Interventions
    Exemestane; Sutent
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2010-03
    Completion
    2012-02
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionExemestane; Sutent
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

    NCT01061411 · start 2010-02-06

    Registered record
    Registry ID
    NCT01061411
    Conditions
    Clear Cell Sarcoma of the Kidney; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
    Interventions
    Dalteparin; Pharmacological Study; Sunitinib Malate
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02-06
    Completion
    2017-04-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Sarcoma of the Kidney; Recurrent Renal Cell Carcinoma; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer
    InterventionDalteparin; Pharmacological Study; Sunitinib Malate
    PhasePhase 1
    Registry statusCompleted

  • Sunitinib in Metastatic Renal Cancer

    NCT01034878 · start 2009-12

    Registered record
    Registry ID
    NCT01034878
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-12
    Completion
    2014-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionSunitinib
    PhasePhase 2
    Registry statusCompleted

  • Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

    NCT01042795 · start 2009-09

    Registered record
    Registry ID
    NCT01042795
    Conditions
    Urothelial Carcinoma; Bladder Cancer
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrothelial Carcinoma; Bladder Cancer
    InterventionSunitinib
    PhasePhase 2
    Registry statusTerminated

  • Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases

    NCT00910039 · start 2009-04

    Registered record
    Registry ID
    NCT00910039
    Conditions
    Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sunitinib malate; cognitive assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-04
    Completion
    2014-04
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventionsunitinib malate; cognitive assessment
    PhasePhase 2
    Registry statusTerminated

  • Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

    NCT01216657 · start 2009-03

    Registered record
    Registry ID
    NCT01216657
    Conditions
    Chemo-refractory Melanoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-03
    Completion
    2013-05
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemo-refractory Melanoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusTerminated

  • Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

    NCT00824538 · start 2009-02

    Registered record
    Registry ID
    NCT00824538
    Conditions
    Breast Cancer
    Interventions
    sunitinib malate; flow cytometry; immunohistochemistry staining method; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-02
    Completion
    2013-12
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionsunitinib malate; flow cytometry; immunohistochemistry staining method; laboratory biomarker analysis
    PhasePhase 2
    Registry statusTerminated

  • Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

    NCT00847015 · start 2009-02

    Registered record
    Registry ID
    NCT00847015
    Conditions
    Bladder Cancer; Urinary Bladder
    Interventions
    Sunitinib; Gemcitabine; cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-02
    Completion
    2012-11
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer; Urinary Bladder
    InterventionSunitinib; Gemcitabine; cisplatin
    PhasePhase 2
    Registry statusCompleted